Pharmacovigilance of antidepressants and antipsychotics in children and adolescents

Phase 3, open-label, single-arm trial of aripiprazole, olanzapine, ziprasidone, melperone, pipamperone and 12 more in mental disorder, major depressive disorder (MDD), anxiety disorder and 5 more, sponsored by University Hospital Würzburg. Primary endpoint: Severe adverse events within 2 weeks (off-label use). Started May 2014; status: completed.